PHAR (Pharming Group N.V. ADS, each representing 10 ordinary shares) Stock Analysis - AI Report

Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR) is a publicly traded Healthcare sector company. As of May 21, 2026, PHAR trades at $12.95 with a market cap of $891.29M and a P/E ratio of 0.00. PHAR moved +0.00% today. Year to date, PHAR is -23.44%; over the trailing twelve months it is +28.70%. Its 52-week range spans $7.31 to $21.34. Analyst consensus is strong buy with an average price target of $38.00. Rallies surfaces PHAR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on PHAR?

Rallies AI research for PHAR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

PHAR Key Metrics

Key financial metrics for PHAR
MetricValue
Price$12.95
Market Cap$891.29M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$21.34
52-Week Low$7.31
Volume2
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest PHAR News

PHAR Analyst Consensus

3 analysts cover PHAR: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.00.

Common questions about PHAR

What is the AI research view on PHAR?
Rallies AI research for PHAR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for PHAR?
Rallies AI research for PHAR combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is PHAR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PHAR. It does not provide personalized investment advice.
PHAR

PHAR